Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by McCall McPherson, PA-C and McCall McPherson. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by McCall McPherson, PA-C and McCall McPherson or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

51: Can We Save Natural Desiccated Thyroid? – The Fight for Patient Access with Jeff Moshal

29:21
 
Share
 

Manage episode 509969437 series 3603332
Content provided by McCall McPherson, PA-C and McCall McPherson. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by McCall McPherson, PA-C and McCall McPherson or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Could the future of natural desiccated thyroid medications—and patient access to them—hang in the balance of FDA regulation?

In this episode of the Modern Thyroid and Wellness Podcast, host McCall McPherson sits down with Jeff Moshal, CEO of Genus Lifesciences Inc., for an in-depth discussion about the critical state of natural desiccated thyroid (NDT) medications, including their flagship product Ren Thyroid. Together, they break down the regulatory hurdles posed by the FDA, the history and safety of NDT, and the manufacturing processes that ensure consistency and quality. Jeff also shares behind-the-scenes efforts through the Thyroid Health Alliance to preserve patient access to these vital medications.

Whether you're a patient who relies on NDT, a clinician prescribing it, or simply curious about the future of thyroid care, this episode is packed with insights, advocacy, and hope.

🔑 Key Topics Covered:

  • History and context behind natural desiccated thyroid (NDT) medications.
  • What makes Ren Thyroid unique and reliable in the current market.
  • FDA approval challenges for legacy thyroid medications and why they matter.
  • Manufacturing standards and quality control measures Genus Lifesciences employs.
  • Differences between NDT and synthetic thyroid drugs—and why many patients prefer NDT.
  • The role of Thyroid Health Alliance in advocating for continued patient access.
  • Safety, dosing consistency, and why trust in NDT is critical for long-term health.
  • How patients and providers can support efforts to keep NDT available.
  • Transparency in the pharmaceutical process and what the future may hold.

👤 About the Guest:

Jeff Moshal is the CEO of Genus Lifesciences Inc., a pharmaceutical company at the forefront of producing high-quality natural desiccated thyroid medication. Under his leadership, Genus has prioritized patient access, safety, and manufacturing integrity while actively working with advocacy groups to meet FDA approval standards.

🌐 Resources & Links:


  continue reading

52 episodes

Artwork
iconShare
 
Manage episode 509969437 series 3603332
Content provided by McCall McPherson, PA-C and McCall McPherson. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by McCall McPherson, PA-C and McCall McPherson or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Could the future of natural desiccated thyroid medications—and patient access to them—hang in the balance of FDA regulation?

In this episode of the Modern Thyroid and Wellness Podcast, host McCall McPherson sits down with Jeff Moshal, CEO of Genus Lifesciences Inc., for an in-depth discussion about the critical state of natural desiccated thyroid (NDT) medications, including their flagship product Ren Thyroid. Together, they break down the regulatory hurdles posed by the FDA, the history and safety of NDT, and the manufacturing processes that ensure consistency and quality. Jeff also shares behind-the-scenes efforts through the Thyroid Health Alliance to preserve patient access to these vital medications.

Whether you're a patient who relies on NDT, a clinician prescribing it, or simply curious about the future of thyroid care, this episode is packed with insights, advocacy, and hope.

🔑 Key Topics Covered:

  • History and context behind natural desiccated thyroid (NDT) medications.
  • What makes Ren Thyroid unique and reliable in the current market.
  • FDA approval challenges for legacy thyroid medications and why they matter.
  • Manufacturing standards and quality control measures Genus Lifesciences employs.
  • Differences between NDT and synthetic thyroid drugs—and why many patients prefer NDT.
  • The role of Thyroid Health Alliance in advocating for continued patient access.
  • Safety, dosing consistency, and why trust in NDT is critical for long-term health.
  • How patients and providers can support efforts to keep NDT available.
  • Transparency in the pharmaceutical process and what the future may hold.

👤 About the Guest:

Jeff Moshal is the CEO of Genus Lifesciences Inc., a pharmaceutical company at the forefront of producing high-quality natural desiccated thyroid medication. Under his leadership, Genus has prioritized patient access, safety, and manufacturing integrity while actively working with advocacy groups to meet FDA approval standards.

🌐 Resources & Links:


  continue reading

52 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play